Biofidelity’s Post

How can we break the cycle that has lead to lung cancer inequitiy for Black patients? Read this thoughtful op-ed from James Lillard in the Personalized Medicine Coalition blog and the Atlanta Journal-Constitution https://hubs.ly/Q02NTLPZ0

** This is critical for patient care, please add your voice today! ** Association for Molecular Pathology (AMP) is inviting comments on the 2024 proposed clinical practice guideline recommendation for lung cancer patients. The deadline to comment on the updated guideline is tomorrow, September 12, 2024. More details at: https://hubs.ly/Q02PzDPY0 #AMP #pathologists #oncologists #labdirectors #patientcare #cancer #lungcancer

We're welcoming some of the newest members of our global team in a series of #WelcomeWednesday posts. This week we're delighted to welcome Shannon! If you're interested in learning more about what it's like to work with us, please visit our careers page to view our open roles https://hubs.ly/Q02MYsgj0

We are thrilled to announce the establishment of our manufacturing facility dedicated to genomic assay production in Cambridge, UK. Simon Knight, Executive Director of Operations, had this to say: “Biofidelity is proud to make reagents here in the UK that will enable simplified, localized biomarker testing solutions and rapid input into research projects for customers around the globe. This manufacturing investment aligns with our commitment to building a sustainable and skilled workforce that will drive the future of genomic research.” Read more here: https://hubs.ly/Q02N_Xs20 #manufacturing #UK #MeetTheTeam

There's still one more day to meet our team at International Association for the Study of Lung Cancer's #WCLC24. Stop by booth #1319 or schedule a meeting to discuss ASPYRE-Lung, a novel approach for non-small cell lung cancer rapid biomarker testing. Click here to schedule a meeting: https://hubs.ly/Q02PdVtw0 #NSCLC #biomarkertesting #genomics4all

Today's panel discussion at Hanson Wade Group's World CDx Conference, moderated by Biofidelity's Dr. Jeffrey Gregg, concluded that a robust global CDx commercialization strategy requires regionalization with pharma partners alongside diagnostic partners with regulatory expertise, broad scale, and low cost. Clinical trials also suffer from sample limitation issues that then translate to clinical testing in the real world making liquid biopsy testing very valuable especially for biomarkers with low prevalence. Panelist Kara O'Brien from Novartis summarized it best: "What we need is a 'patient first' approach to testing near the patient. That will usher true global impact."

Team Biofidelity enjoyed this evening's Cirque du Sip at Hanson Wade Group's World CDx conference. There's one more day of the conference, come join us! Our own Dr. Jeffrey Gregg, VP of Medical Affairs, is moderating a panel featuring Kara O'Brien, Executive Director, Global Precision Diagnostics, Market & Ecosystem Shaping Novartis and Zheng Feng, Director & Head, Clinical Genomics Clinical Biomarker Technologies EMD Serono, Inc. Join their discussion TOMORROW, Friday, Sept 6th at 11:35am (Track C) !https://hubs.ly/Q02NVbhD0 #biomarkers #decentralization

Will you be at @IASLC's 2024 World Conference on Lung Cancer in San Diego this weekend? If so, we want to meet you! Stop by booth #1319 or schedule a meeting to discuss ASPYRE-Lung, a novel approach for non-small cell lung cancer rapid biomarker testing. Click here to schedule a meeting: https://hubs.ly/Q02MgZwk0 #WCLC24 #NSCLC #biomarkertesting #genomics4all